Primary source: Inspections and Compliance
Approval of Rasonque requires updates to product labeling to include new indications and safety information following its designation as a Breakthrough Therapy and Orphan Drug.
This approval introduces a significant therapeutic option for a historically difficult-to-treat cancer, potentially enhancing survival and quality of life for patients with metastatic pancreatic adenocarcinoma.
Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.
On August 26, 2026, the FDA approved Rasonque (daraxonrasib) as a RAS inhibitor for adults with metastatic pancreatic adenocarcinoma who have undergone prior systemic treatment or are unsuitable for multiagent therapy. The approval arose from a clinical trial showing a median overall survival improvement from 6.7 to 13.2 months compared to standard chemotherapy.
What changed: Approval of Rasonque requires updates to product labeling to include new indications and safety information following its designation as a Breakthrough Therapy and Orphan Drug.
Why it matters: This approval introduces a significant therapeutic option for a historically difficult-to-treat cancer, potentially enhancing survival and quality of life for patients with metastatic pancreatic adenocarcinoma.
Practical implication: Initiate the update of labeling materials for Rasonque to reflect the new FDA approval and ensure compliance with reporting requirements for newly approved therapies.
Published from the regulator source ingestion pipeline after PV impact triage.
Review and verify that any cosmetic products sourced or distributed comply with the manufacturers listed in the updated QUEST system.
Annual reviews of new information will be conducted to update the summary, requiring continuous monitoring and data submission in response to findings.
Marketing authorization holders (MAHs) must review and potentially update their product labeling to align with the new regulations by 11 April 2029 for products authorized before 11 May 2024.
Regulatory Intelligence leads should initiate monitoring of feedback and prepare for potential regulatory adjustments related to the specified substances.
